Drugmaker Eli Lilly & Co. said it expects to begin human testing as soon as next month for an experimental Covid-19 treatment that uses antibodies derived from the blood of people who have recovered from the viral disease.

The testing could yield results by late summer and, if successful, potential emergency authorization by the U.S. Food and Drug Administration by early fall, Lilly Chief Executive David Ricks said in an interview Thursday.

The...